A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

As­traZeneca has al­ready made bil­lions on their PARP Lyn­parza, work­ing along­side ri­vals like GSK, Pfiz­er and Clo­vis to demon­strate the widen­ing po­ten­tial of a drug that throws a mon­key wrench in the DNA dam­age re­pair process — al­low­ing drugs to kill off can­cer cells. Now a group of in­ves­ti­ga­tors at the Uni­ver­si­ty of Michi­gan have pub­lished new re­search to show how a sim­i­lar ap­proach tar­get­ing Wee1 has the po­ten­tial to do the same for tough-to-treat cas­es of ad­vanced pan­cre­at­ic can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER